Overview of clinical trials with new agents.
Charpentier
B
B
Nephrology Department, University Hospital of Bicêtre, Kremlin Bicêtre, France.
Hiesse
C
C
Durrbach
A
A
Ammor
M
M
Von Ey
F
F
Kechrid
C
C
Kriaa
F
F
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000077552:Basiliximab; D002986:Clinical Trials as Topic; D000077561:Daclizumab; D004359:Drug Therapy, Combination; D006085:Graft Survival; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality / Q000502:physiology; D015337:Multicenter Studies as Topic; D011993:Recombinant Fusion Proteins; D020123:Sirolimus / Q000627:therapeutic use; D015996:Survival Rate; D014181:Transplantation Immunology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab; D000077561:Daclizumab; D020123:Sirolimus